Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-Exendin-4
- Development stage
- Phase 2
- Lead developer
- Radboud University Medical Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-Exendin-4 is a diagnostic radiopharmaceutical composed of the peptide exendin-4, a potent glucagon-like peptide 1 receptor (GLP-1R) agonist, conjugated to the chelator NODAGA and labeled with the positron-emitting radionuclide gallium-68. Exendin-4 specifically binds to GLP-1 receptors, which are highly expressed on pancreatic β-cells and certain neuroendocrine tumors such as insulinomas. The drug is used in PET/CT imaging for non-invasive localization of insulinomas and focal lesions in congenital hyperinsulinism (CHI), offering high sensitivity and superior image quality compared to other tracers like 18F-DOPA. Its mechanism involves targeting GLP-1R for visualization rather than therapeutic modulation[1][3][4][10]. Developed primarily by Radboud University Nijmegen, it remains investigational with its highest development phase being preclinical or early clinical studies[2].
- Brand names
- PanTracer
- Other names
- 68Ga-NODAGA-exendin-4Gallium-68 exendin-4Gallium68 exendin-4Gallium 68 exendin-468Ga-exendin-4-Azienda Ospedaliero-Universitaria di Parma
02
Targets
Beyond the preview
Go deeper on 68Ga-NODAGA-Exendin-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-Exendin-4.